ENvue Medical, Inc.

What they do

The company runs two wholly-owned subsidiaries. NanoVibronix Ltd., incorporated in Israel, develops non-invasive biological response-activating devices for biofilm prevention, pain therapy and wound healing that are designed for home use without medical professional assistance, sold under the PainShield and UroShield names. ENvue Medical Holdings LLC is a medical device company in enteral feeding, in the initial stage of commercializing its FDA 510(k)-cleared ENvue System, which assists in insertion of a feeding tube.

Revenue drivers

• ENvue systems and tubes — Enteral feeding navigation products sold to hospitals; represented 77% of revenues for the three months ended June 30, 2026, up from 10% a year earlier, with ENvue revenue growing about 275% to approximately $184 in that quarter.
• PainShield and monthly kits — NanoVibronix home-use pain therapy product; 16% of revenues for the three months ended June 30, 2026, down from 87% a year earlier due to a production halt tied to the war in Israel and manufacturing relocation.
• UroShield and monthly kits — NanoVibronix biofilm-prevention product; 2% of revenues for the three months ended June 30, 2026, and not separately broken out in the prior-year quarter.
• Other products — 5% of revenues for the three months ended June 30, 2026, versus 3% for the three months ended June 30, 2025.

Recent performance

For the three months ended June 30, 2026, revenues were approximately $239, down about 51.6% from approximately $494 a year earlier; the decline came mainly from the halt in PainShield/UroShield production caused by the war in Israel and the relocation of that manufacturing to the United States. ENvue revenue partially offset the drop, rising roughly 275% from approximately $49 to approximately $184. Gross loss for the quarter widened to approximately $266 from $35, an increase of about 660%, driven largely by $140 of technology amortization. For the full year 2025, revenue was $2.6M and net loss was $18.2M, with operating cash use of $9.4M.

Strategy

Following the February 2025 merger, management has been consolidating functions and resources across the combined organization to reduce duplication and improve operating efficiency, including sharing personnel and technical resources across the two product platforms. The company completed the transition of NanoVibronix manufacturing operations to the United States in August 2026, and production has been re-established. ENvue's stated mission is to be an innovation leader in enteral feeding, focused on advanced, personalized navigation solutions and improving patient outcomes across the continuum of care. Management expects PainShield/UroShield revenues to resume now that production has restarted, though it gives no assurance on timing or extent of recovery.

Risks

• History of losses — The company has a history of losses, reported a $18.2M net loss for 2025 and a gross loss of approximately $266 in the June 2026 quarter, and expects to continue incurring losses.
• Need for additional capital — Management states that without additional capital its clinical trials and product development will be limited and long-term viability threatened, while raising capital could dilute existing stockholders.
• Nasdaq listing compliance — A delisting notice or listing-rule failure was disclosed on July 10, 2026, and the company identifies regaining and maintaining Nasdaq continued listing compliance as a risk.
• Operations in Israel — NanoVibronix operations are exposed to political, economic and military instability in Israel; the war there already caused a halt in PainShield/UroShield production and a manufacturing relocation.

Outlook

Management states that the NanoVibronix manufacturing transition to the United States was completed in August 2026 and production has been re-established, and it expects PainShield/UroShield revenues to resume, though it provides no assurance as to timing or extent of any recovery. The company continues to pursue expansion of the installed hospital base and adoption of the ENvue Navigation Platform, and has consolidated functions across the two platforms to reduce duplication. No specific financial guidance is provided in the excerpts.